Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ; T0 _( x* `- v9 \9 {3 x& h* y5 ^
N5 d* ]1 S9 L" {% j" e3 L9 ?+ j* C( K% t* |# ~. t- l
Sub-category:. K8 h. i/ ~* T+ G; a0 w- J
Molecular Targets
5 r2 _# E* [. Z6 g: [4 J% j; I: e, _) V" q4 I$ m
4 n$ w. Q. @: k- j8 {
Category:
6 J$ \3 B- H" {- r/ n5 N6 `% rTumor Biology
" U! a. r! i0 I1 W* W1 v/ f' a, T W
0 a8 V) d9 y$ I1 W$ u2 uMeeting:5 @. r; @$ h1 {5 Z
2011 ASCO Annual Meeting
! v* q! Q' l, }$ ~/ _, k
. Y9 h# n$ O2 R+ l( Z
l% V/ I) t+ c, p) `Session Type and Session Title:2 E8 x2 N/ J" E: M! I9 b
Poster Discussion Session, Tumor Biology $ n! B6 J- C# [" {# I
B4 U8 X) h& C5 P( r: `# U9 ]! m% J$ x+ V9 [/ H
Abstract No:" N9 ^* v% O5 ?& a7 Q9 o- s
10517 * m7 v/ ^3 N4 [0 P) o! m9 e/ u
/ r( \5 Q2 m9 b; E, P, d( f1 k% j: x+ k9 A
Citation:- r" o0 l, G, [, c$ e( ~1 j; c9 i
J Clin Oncol 29: 2011 (suppl; abstr 10517)
' _: T* l' E# Y) }& y9 ]
# x) ^# Q/ w+ a/ ~; g
- X" y; d, q: @! fAuthor(s):
F9 C( d6 d, N0 B# LJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 S$ o% h0 Z/ f4 [$ ]4 G8 D
! ~6 v" I, t, g9 f W0 }( y, Z3 o1 q* x/ O
3 S( A2 Y+ t$ b. I
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.8 ]- B2 T. _- F4 ]
, \9 X" \! k$ F
Abstract Disclosures' [# b) t" b! Q+ x" [
7 {1 c, r1 ~" l! _Abstract:
1 a* b) N$ @, k. _1 A
, S$ ~/ s# O/ A6 ]2 [# g. w, j+ T' ~9 s
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ i6 n( a+ D6 O' Y
, i: t: l6 s2 I- W# l) g! q% P
& N# t p1 J: S' {( y I |